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ment of pure aortic regurgitation.
METHODS Transapical TAVI with a J-ValveTM system for the treat-
ment of pure aortic regurgitation was performed in
18 patients (Mean age 73.8 3.7 years). All patients were considered
high risk for surgery (Mean logistic Euro-SCORE 24.14.5 %).The
J-ValveTM prosthesis consists of a porcine root valve mounted on a
low-proﬁle self-expanding nitinol stent. This device is featured by
three U-shape anatomically oriented devices -“graspers”, which could
facilitate intuitive ‘self-positioning’ during valve implantation
and provide extra-radial ﬁxation by embracing the native valve leaf-
lets. Procedural results and clinical outcomes up to 30 days were
analyzed.
RESULTS Implantation was successful in 17 of 18 cases (successful
rate 94%), Mean aortic annulus diameter was 25.71.5 mm, six 25mm
and twelve 27mm prosthesis was used. One patient was converted
to open-heart procedure due to valve dislodgment into the ascending
aorta. Mean transvalvular gradient is favorable after
valve implantation (6.91.2mmHg). Post-procedural aortic regurgita-
tion was none/ trace in 15 of 17 and mild in 2 of 17 patients at 30 days
follow-up. No mortality was noted at 30 days follow-up. Pacemaker
implantation for new 3rd AVB was necessary in 2 patients (11%).
CONCLUSIONS Aortic regurgitation remains a challenging pathology
for TAVI. This study revealed the J-ValveTM system is a potential
reasonable option in this subset of patients.
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BACKGROUND Residual aortic regurgitation (AR) following trans-
catheter aortic valve replacement (TAVR) has been reported to be
associated with increased risk of mortality. Quantitation of AR after
TAVR by Doppler-echocardiography remains challenging and cardio-
vascular magnetic resonance (CMR) has been suggested to be more
accurate. However, no data exist on the prognostic value of AR as
assessed by CMR post-TAVR. The objective of this study was therefore
to evaluate the impact of AR as determined by CMR following TAVR
on clinical outcomes.
METHODS 135 patients from 3 centers were included, and AR was
quantitated with the use of regurgitant fraction (RF) measured by
phase-contrast velocity mapping CMR, and using a multi-parametricapproach according to VARC-2 criteria by Doppler-echocardiography.
The median follow-up was 25 [12-41] months and clinical outcomes
included all-cause and cardiac mortality, rehospitalization for heart
failure (HF) and the need for valve prosthesis reintervention.
RESULTS Moderate or severe AR was detected in only 17.1% of the
patients by echocardiography, but 33.1% by CMR, with a modest cor-
relation between both methods (Rs¼0.595; p<0.001). Mean RF by
CMR was 15.7  12.4%, and a higher RF after TAVR was independently
associated with increased risk of all-cause mortality (HR: 1.19 for each
increase of 5% [95% CI of 1.02-1.38]; p¼0.025) and the combined
endpoint of mortality and rehospitalization (HR: 1.21 for each increase
of 5% [95% CI of 1.08-1.35]; p<0.001). A higher RF was also associated
with increased rates of cardiac death, rehospitalization for HF or valve
prosthesis reintervention (HR: 1.20 for each increase of 5% [95% CI of
1.08-1.34]; p¼0.001). Patients with a RF 30% had a combined event
rate of cardiac death, rehospitalization for HF or valve prosthesis
reintervention of 50% at 2-year follow-up (vs. 13% for RF<30%;
p<0.001).
CONCLUSIONS High degrees of CMR-quantiﬁed AR were associated
with increased mortality and poorer clinical outcomes following
TAVR, while echocardiography underestimated AR severity. Quanti-
fying AR by CMR may help to better deﬁne those patients with sig-
niﬁcant residual AR and the eventual need for additional treatment
after TAVR.
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System has a non-metallic design with a pressurized support struc-
ture, which allows precise positioning, retrieval and full hemody-
namic assessment of valve performance prior to permanent
implantation. The DISCOVER registry is a European prospective
multicenter study to evaluate the real-world performance of the DFM
valve for the treatment of severe symptomatic aortic stenosis in
extreme risk patients.
METHODS Patients with a logistic Euro Score  20 or other high
surgical risk co-morbidities not reﬂected by the logistic Euro
Score were enrolled at twenty-two (22) participating centers in
Europe. All endpoint-related adverse events are being adjudicated
by an independent clinical event committee. In this abstract,
we provide a preliminary report on 30d results in 275 patients and
1-year results in the ﬁrst 125 DISCOVER registry patients treated
with a Direct Flow Medical valve. Data from additional patients
will become available shortly and will be included in the
presentation.
RESULTS Patients were 82.65.4 years, and 41% of patients were
female. The logistic Euro Score and STS were 18.914.7% (N¼273) and
8.18.3% (N¼148), respectively. Other co-morbidities included coro-
nary artery disease in 65.1%, prior CABG 16.7%, and chronic kidney
disease 32.4%. In this population, 5.1% (n¼14) of patients received a
23mm valve, 42.5% (n¼117) a 25mm valve, 34.5% (n¼95) a 27mm
valve, and 13.1% (n¼36) a 29mm valve. At 30 days, freedom from all-
cause mortality was 98.2% (270/275) and freedom from death and
major stroke was 96.4% (265/275). A new permanent pacemaker was
implanted in 12.7% (35/275). The rate of major vascular complications
was 3.6% (10/275), and the rate of acute kidney injury stage 2 or 3
was 3.3% (9/275). Paravalvular regurgitation at 30 days was none or
trace in 81.0% (149/184) of patients, moderate in 2.7% (5/184)
and severe in no patients, with 86.4% (159/184) in NYHA functional
class I or II. At the time of abstract submission, 1 year data on 125
patients were available. In this population, freedom from all-cause
mortality at 1 year was 87.2% (109/125) and freedom from all-cause
mortality and major stroke was 82.4% (103/125). A new permanent
pacemaker was implanted in 2.4% (3/125) of these patients between
30 days and 1 year. Paravalvular regurgitation was none or trace in
91.4% (64/70) of patients, moderate in 1.4% (1/70) and severe in no
patients, and 84.0% (68/81) of patients were in NYHA functional class
I or II at 1 year.
CONCLUSIONS The Direct Flow Medical Trans-catheter Aortic Valve
System demonstrates excellent real-world outcomes in extreme sur-
gical risk patients with severe aortic stenosis.
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BACKGROUND Recently, a robotic system for performing remote-
controlled angioplasty and stent placement was approved for clinical
use in the US. This robotic system allows the operator to perform
percutaneous coronary intervention (PCI) while seated in a lead-lined
cockpit, thereby minimizing radiation exposure and eliminating the
need for lead apparel. To date, available data describing robotic PCI
have been obtained exclusively using femoral arterial access. This
study was performed to describe the initial clinical experience and
procedure outcomes of robotic PCI performed using radial arterial
access.
METHODS Data were collected from consecutive robotic PCI cases
performed at a single center using radial arterial access. Target
coronary lesions were classiﬁed angiographically according to the
ACC/AHA lesion classiﬁcation system. The primary measure of in-
terest was procedure success, deﬁned as <30% residual stenosis
after PCI in the absence of associated death or repeat revasculari-
zation prior to hospital discharge. Access site complications,
including bleeding or radial artery occlusion, were assessed.Procedure duration, deﬁned as the time from sheath insertion to
removal of the guide catheter, was recorded and compared to all
manual PCI cases performed at the same center using radial arterial
access during the same time period.
RESULTS We studied 55 consecutive patients (age 62  11; 78%
male) undergoing robotic PCI using radial arterial access. The clinical
presentation of these patients was myocardial infarction in 31%,
unstable angina in 60%, and stable symptoms in 9%. Robotic PCI
was attempted on 62 lesions overall, with varying baseline angio-
graphic complexities (Type A 19%, Type B1 27%, Type B2 34%, Type
C 19%). Robotic PCI resulted in procedure success in 57 of 62 (92%)
lesions. In 4 of 5 cases in which procedure success was not achieved,
lesions were classiﬁed as ACC/AHA Type C. None of the patients
undergoing robotic PCI experienced death or repeat revasculariza-
tion prior to hospital discharge and there were no access site com-
plications. Robotic PCI was associated with a 13-minute increase in
procedure duration compared to 552 consecutive PCI cases per-
formed manually from the radial approach during the same time
period (robotic PCI 68  22 minutes vs. manual PCI 55  26 minutes;
p<0.001).
CONCLUSIONS The present observations represent preliminary evi-
dence that robotic PCI using radial arterial access is feasible and
associated with acceptable clinical outcomes. Additional studies are
needed to further evaluate the clinical outcomes associated with ro-
botic PCI and to determine if robotic PCI procedure duration, which
we demonstrate to be longer than the traditional manual approach in
this early clinical experience, will shorten as additional clinical
experience is gained.
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BACKGROUND The repositionable and fully retrievable Lotus
Valve (Boston Scientiﬁc, Marlborough, MA, USA) was designed to
facilitate accurate positioning and minimize paravalvular regurgita-
tion in patients with severe aortic stenosis. This analysis will present
the ﬁrst report of 2-year outcomes from the REPRISE II CE-Mark
study.
METHODS The REPRISE II study is a prospective, single-arm trial that
enrolled patients who are at high or extreme surgical risk and
aged 70 years at 14 centers in Australia and Europe. Patients had
severe, symptomatic calciﬁc aortic stenosis and were deemed to be at
high or extreme risk for surgery based on assessment by the Heart
Team.
RESULTS Among 120 enrolled patients, the mean age was 84.45.3
years, 57% (68/120) were female, and mean STS Score was 7.14.6.
The mean baseline aortic valve area was 0.70.2cm2 and the mean
aortic valve pressure gradient was 46.415.0mmHg. All patients
were successfully implanted with a Lotus Valve; full valve retrieval
